Randomized, multicenter study comparing the immediate adjuvant radiotherapy associate with hormonal therapy of LH-RH analogue (Decapeptyl LP) vs delayed radiotherapy until biochemical relapse associated with hormonal therapy of LH-RH analogue (Decapeptyl LP) in patients with operable prostate cancer pT3 R1 pN0 or pNx at intermediate risk.

Trial Profile

Randomized, multicenter study comparing the immediate adjuvant radiotherapy associate with hormonal therapy of LH-RH analogue (Decapeptyl LP) vs delayed radiotherapy until biochemical relapse associated with hormonal therapy of LH-RH analogue (Decapeptyl LP) in patients with operable prostate cancer pT3 R1 pN0 or pNx at intermediate risk.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 25 May 2018

At a glance

  • Drugs Triptorelin (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 May 2018 Planned primary completion date changed from 1 Dec 2022 to 1 Apr 2022.
    • 06 May 2018 Status changed from recruiting to active, no longer recruiting.
    • 11 Dec 2012 Last checked against European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top